Who is sponsoring NCT02969265?

NCT02969265 is sponsored by Takeda.

What condition does NCT02969265 study?

NCT02969265 studies Hypertension.

What drugs are being tested in NCT02969265?

Interventions: Amlodipine, TCV-116CCB, Amlodipine Placebo, TCV-116CCB Placebo.

What is the status of NCT02969265?

NCT02969265 is currently WITHDRAWN.

Last reviewed 2017-06-09 · How we verify

An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension

NCT02969265 PHASE3 WITHDRAWN

The purpose of this study is to evaluate the efficacy and safety of TCV-116CCB (candesartan cilexetil and amlodipine besylate fixed-dose combination) in Chinese participants with mild to moderate hypertension who do not reach target blood pressure following 4 weeks of treatment with amlodipine monotherapy.

Details

Lead sponsor	Takeda
Phase	PHASE3
Status	WITHDRAWN
Start date	Tue May 09 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jul 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Hypertension

Interventions

Amlodipine
TCV-116CCB
Amlodipine Placebo
TCV-116CCB Placebo

Countries

China